{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:14:30Z","timestamp":1793830470208,"version":"4.6.1"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The aims of this study were to perform a comprehensive review and meta-analyses and to report pooled diagnostic results on CXCR4-targeted PET, particularly considering detection, visualization, and prognostication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      This study followed PRISMA-DTA. A systematic search was conducted on major medical literature databases up to March 1, 2024. The search strategy was designed to include CXCR4 PET studies in hematologic malignancies. A random-effects model combined sensitivity values derived from 2-by-2 contingency tables. Pooled means for SUV\n                      <jats:sub>max<\/jats:sub>\n                      were computed. Analyses were performed by R software.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The initial search resulted in a total of 1428 studies. Ultimately, 18 were eligible for systematic review and meta-analytic calculations. Twelve studies (320 patients) included B-cell lymphoma. The pooled detection rate of CXCR4 PET was 99.4% (95% confidence interval [CI]: 88.3%\u2013100%). Marginal zone lymphoma was investigated in 5 studies (209 patients), with a pooled sensitivity of 97.6% (95% CI: 79.7%\u201399.8%). In studies on central nervous system lymphoma, CXCR4 PET demonstrated 100% accuracy at both patient and lesion levels. Also, it demonstrated a significantly higher tumor-to-background ratio than\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET. For multiple myeloma, 5 studies (116 patients) showed a patient-level pooled sensitivity of 77.8% (95% CI: 64.4%\u201387.2%), whereas\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET had 65.0% (95% CI: 55.2%\u201373.7%). The pooled SUV\n                      <jats:sub>max<\/jats:sub>\n                      for CXCR4 PET was 13.6 (95% CI: 9.3\u201317.8) versus 9.0 (95% CI: 6.3\u201311.7) for\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET. Additionally, CXCR4 PET-derived parameters were significant predictors of survival in multiple myeloma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CXCR4 PET can be a helpful imaging tool for evaluating hematologic malignancies, particularly in B-cell lymphoma and multiple myeloma patients. In specific clinical scenarios, it appears to be superior compared with the current standard-of-care imaging.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005426","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T13:16:58Z","timestamp":1726060618000},"page":"e7-e16","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["CXCR4-Targeted PET Imaging in Hematologic Malignancies"],"prefix":"10.1097","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6598-7190","authenticated-orcid":false,"given":"Mohammadreza","family":"Chavoshi","sequence":"first","affiliation":[{"name":"Joint Department of Medical Imaging, University Medical Imaging Toronto, University Health Network, Mount Sinai Hospital & Women\u2019s College Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2271-9764","authenticated-orcid":false,"given":"Seyed Ali","family":"Mirshahvalad","sequence":"additional","affiliation":[{"name":"Joint Department of Medical Imaging, University Medical Imaging Toronto, University Health Network, Mount Sinai Hospital & Women\u2019s College Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3592-3000","authenticated-orcid":false,"given":"Andres","family":"Kohan","sequence":"additional","affiliation":[{"name":"Joint Department of Medical Imaging, University Medical Imaging Toronto, University Health Network, Mount Sinai Hospital & Women\u2019s College Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3357-1849","authenticated-orcid":false,"given":"Claudia","family":"Ortega","sequence":"additional","affiliation":[{"name":"Joint Department of Medical Imaging, University Medical Imaging Toronto, University Health Network, Mount Sinai Hospital & Women\u2019s College Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3726-8994","authenticated-orcid":false,"given":"Ur","family":"Metser","sequence":"additional","affiliation":[{"name":"Joint Department of Medical Imaging, University Medical Imaging Toronto, University Health Network, Mount Sinai Hospital & Women\u2019s College Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Farag","sequence":"additional","affiliation":[{"name":"Joint Department of Medical Imaging, University Medical Imaging Toronto, University Health Network, Mount Sinai Hospital & Women\u2019s College Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0287-7124","authenticated-orcid":false,"given":"Robert","family":"Kridel","sequence":"additional","affiliation":[{"name":"Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4687-4582","authenticated-orcid":false,"given":"David","family":"Hodgson","sequence":"additional","affiliation":[{"name":"Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sita","family":"Bhella","sequence":"additional","affiliation":[{"name":"Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Kukreti","sequence":"additional","affiliation":[{"name":"Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Veit-Haibach","sequence":"additional","affiliation":[{"name":"Joint Department of Medical Imaging, University Medical Imaging Toronto, University Health Network, Mount Sinai Hospital & Women\u2019s College Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"bib1-20241203","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/MNM.0000000000001719","article-title":"Diagnostic value of [68Ga]Ga-pentixafor versus [18F]FDG PET\/CTs in non-small cell lung cancer: a head-to-head comparative study","volume":"44","year":"2023","journal-title":"Nucl Med Commun"},{"key":"bib3-20241203","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.3390\/cancers14153814","article-title":"The role of [68Ga] Ga-Pentixafor PET\/CT or PET\/MRI in lymphoma: a systematic review","volume":"14","year":"2022","journal-title":"Cancer"},{"key":"bib4-20241203","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.biocel.2017.12.018","article-title":"The good and bad faces of the CXCR4 chemokine receptor","volume":"95","year":"2018","journal-title":"Int J Biochem Cell Biol"},{"key":"bib5-20241203","doi-asserted-by":"crossref","first-page":"100253","DOI":"10.1016\/j.jbo.2019.100253","article-title":"The role of CXCR4 in multiple myeloma: cells\u2019 journey from bone marrow to beyond","volume":"17","year":"2019","journal-title":"Journal of bone oncology"},{"key":"bib6-20241203","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1080\/17474086.2020.1839885","article-title":"Chemokine receptor CXCR4: an important player affecting the molecular-targeted drugs commonly used in hematological malignancies","volume":"13","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"Supplement 2","key":"bib7-20241203","doi-asserted-by":"crossref","first-page":"77S","DOI":"10.2967\/jnumed.116.186874","article-title":"CXCR4 ligands: the next big hit?","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib8-20241203","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.7150\/ijbs.82317","article-title":"CXCL12-CXCR4\/CXCR7 axis in cancer: from mechanisms to clinical applications","volume":"19","year":"2023","journal-title":"Int J Biol Sci"},{"key":"bib9-20241203","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2174\/1389557523666221216095821","article-title":"Nuclear medicine application of pentixafor\/pentixather targeting CXCR4 for imaging and therapy in related disease","volume":"23","year":"2023","journal-title":"Mini Rev Med Chem"},{"key":"bib10-20241203","doi-asserted-by":"crossref","first-page":"34641","DOI":"10.18632\/oncotarget.26214","article-title":"Correction: screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using (64)cu-plerixafor PET","volume":"9","year":"2018","journal-title":"Oncotarget"},{"key":"bib11-20241203","doi-asserted-by":"crossref","first-page":"8264","DOI":"10.7150\/thno.45537","article-title":"A new class of pentixafor-and pentixather-based theranostic agents with enhanced CXCR4-targeting efficiency","volume":"10","year":"2020","journal-title":"Theranostics"},{"key":"bib12-20241203","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1007\/s00259-022-05849-y","article-title":"CXCR4-targeted theranostics in oncology","volume":"49","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib13-20241203","first-page":"m2632","article-title":"Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): explanation, elaboration, and checklist","volume":"370","year":"2020","journal-title":"BMJ"},{"key":"bib14-20241203","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"bib16-20241203","first-page":"40","article-title":"meta: an R package for meta-analysis","volume":"7","year":"2007","journal-title":"R News"},{"key":"bib17-20241203","first-page":"1","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","year":"2010","journal-title":"J Stat Softw"},{"key":"bib18-20241203","first-page":"15","article-title":"Meta-analysis of diagnostic accuracy with mada","volume":"1","year":"2015","journal-title":"R Packag"},{"key":"bib19-20241203","first-page":"1687","article-title":"Imaging of CXC motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using 68Ga-pentixafor PET","volume":"63","year":"2022","journal-title":"J Nucl Med"},{"key":"bib20-20241203","first-page":"1","article-title":"CXCR4-directed PET\/CT with [68Ga] pentixafor in central nervous system lymphoma: a comparison with [18F] FDG PET\/CT","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"bib21-20241203","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.2967\/jnumed.123.266074","article-title":"Chemokine receptor PET\/CT provides relevant staging and management changes in marginal zone lymphoma","volume":"64","year":"2023","journal-title":"J Nucl Med"},{"key":"bib22-20241203","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.7150\/thno.31032","article-title":"Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [68Ga] Ga-Pentixafor-PET\/MRI","volume":"9","year":"2019","journal-title":"Theranostics"},{"key":"bib23-20241203","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2967\/jnumed.120.241703","article-title":"CXCR4-targeted PET imaging of central nervous system B-cell lymphoma","volume":"61","year":"2020","journal-title":"J Nucl Med"},{"key":"bib24-20241203","first-page":"1","article-title":"Chemokine receptor\u2013targeted PET\/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [18F] FDG","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib25-20241203","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40336-021-00458-5","article-title":"[68Ga]-Pentixafor PET\/CT imaging of lymphoproliferative malignancies","volume":"9","year":"2021","journal-title":"Clin Transl Imaging"},{"key":"bib26-20241203","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2967\/jnumed.119.226134","article-title":"68Ga-Pentixafor PET\/CT for imaging of chemokine receptor 4 expression in Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphoma: comparison to 18F-FDG PET\/CT","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib27-20241203","doi-asserted-by":"crossref","first-page":"567","DOI":"10.7150\/thno.48620","article-title":"CXCR4 PET imaging of mantle cell lymphoma using [68Ga] pentixafor: comparison with [18F] FDG-PET","volume":"11","year":"2021","journal-title":"Theranostics"},{"key":"bib28-20241203","first-page":"240","article-title":"CXCR4 PET\/MRI for follow-up of gastric mucosa\u2013associated lymphoid tissue lymphoma after first-line helicobacter pylori eradication","volume":"139","year":"2022","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"bib29-20241203","first-page":"1","article-title":"Preliminary evidence of imaging of chemokine receptor-4-targeted PET\/CT with [68Ga] pentixafor in non-Hodgkin lymphoma: comparison to [18F] FDG","volume":"10","year":"2020","journal-title":"EJNMMI Res"},{"key":"bib30-20241203","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/RLU.0000000000003760","article-title":"Chemokine receptor 4\u2013targeted 68Ga-pentixafor PET\/CT in response assessment of Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphoma: comparison to 18F-FDG PET\/CT","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib31-20241203","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/RLU.0000000000003404","article-title":"Assessment of central nervous system lymphoma based on CXCR4 expression in vivo using [68Ga] pentixafor-PET\/MRI","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib32-20241203","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s12149-021-01652-1","article-title":"Prognostic significance of 68Ga-pentixafor PET\/CT in multiple myeloma recurrence: a comparison to 18F-FDG PET\/CT and laboratory results","volume":"35","year":"2021","journal-title":"Ann Nucl Med"},{"key":"bib33-20241203","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7150\/thno.16576","article-title":"[68Ga] pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma\u2014comparison to [18F] FDG and laboratory values","volume":"7","year":"2017","journal-title":"Theranostics"},{"key":"bib34-20241203","first-page":"210","article-title":"Evaluation of chemokine receptor-4 expression by 68Ga-pentixafor PET\/CT in patients with multiple myeloma","volume":"33","year":"2020","journal-title":"International Journal of Hematology and Oncology"},{"key":"bib35-20241203","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","article-title":"Chemokine receptor-4 targeted PET\/CT with 68Ga-pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET\/CT","volume":"47","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib36-20241203","doi-asserted-by":"crossref","first-page":"477","DOI":"10.15252\/emmm.201404698","article-title":"In vivo molecular imaging of chemokine receptor CXCR 4 expression in patients with advanced multiple myeloma","volume":"7","year":"2015","journal-title":"EMBO Mol Med"},{"key":"bib37-20241203","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.7150\/thno.75847","article-title":"Reduced splenic uptake on 68Ga-pentixafor-PET\/CT imaging in multiple myeloma\u2014a potential imaging biomarker for disease prognosis","volume":"12","year":"2022","journal-title":"Theranostics"},{"key":"bib38-20241203","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.3390\/cancers12082333","article-title":"18F-FDG, 11C-methionine, and 68Ga-pentixafor PET\/CT in patients with smoldering multiple myeloma: imaging pattern and clinical features","volume":"12","year":"2020","journal-title":"Cancer"},{"key":"bib39-20241203","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2967\/jnumed.121.262206","article-title":"68Ga-pentixafor PET\/CT for detection of chemokine receptor CXCR4 expression in myeloproliferative neoplasms","volume":"63","year":"2022","journal-title":"J Nucl Med"},{"key":"bib40-20241203","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3324\/haematol.2016.142976","article-title":"Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia","volume":"101","year":"2016","journal-title":"Haematologica"},{"key":"bib41-20241203","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cpet.2022.03.001","article-title":"18F-FDG versus non-FDG PET tracers in multiple myeloma","volume":"17","year":"2022","journal-title":"PET clinics"},{"key":"bib42-20241203","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.ejca.2005.11.037","article-title":"The role of anatomic and functional staging in myeloma: description of Durie\/Salmon plus staging system","volume":"42","year":"2006","journal-title":"Eur J Cancer"},{"key":"bib43-20241203","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","article-title":"Multiple myeloma, version 3.2021, NCCN clinical practice guidelines in oncology","volume":"18","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"bib44-20241203","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2967\/jnumed.118.210997","article-title":"Feasibility of CXCR4-directed radioligand therapy in advanced diffuse large B-cell lymphoma","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib45-20241203","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2967\/jnumed.115.167361","article-title":"First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu-and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra-and extramedullary disease","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib46-20241203","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.7150\/thno.19050","article-title":"CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma","volume":"7","year":"2017","journal-title":"Theranostics"},{"key":"bib47-20241203","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/RLU.0000000000004638","article-title":"68Ga-pentixafor PET\/MRI for treatment response assessment in mantle cell lymphoma","volume":"48","year":"2023","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T18:00:16Z","timestamp":1733248816000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005426"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005426","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,11]]}}}